News

Two tumor cells, one with forcefield. two blue spheres with green and purple spheres on them

Kinase Closed: Shutting Down Cancer's Escape Routes

MIT News

Forest White and Cameron Flower PhD ’24 have uncovered why drugs that inhibit tyrosine kinase signaling pathways, such as imatinib (Gleevec), fail in some patients.  By analyzing tumor phosphoproteomics, the White Lab team found that many resistant cells are intrinsically wired to resist tyrosine kinase inhibitors: backup signaling networks are already running to support vital functions such as cell growth and division, even when tyrosine kinase inhibitors work as intended. 

As reported in Proceedings of the National Academy of Sciences, researchers overcame this resistance in cell models by pairing a tyrosine kinase inhibitor with a drug that targets the backup pathway—an approach currently in clinical trials for lung cancer. 

“We are really excited to watch these clinical trials and to see how well patients do on these combinations. And I really think there’s a future for using tyrosine phosphoproteomics to guide this clinical decision-making,” White says. The research was funded in part by the MIT Center for Precision Cancer Medicine.
 

Filter by

Filter by Title/Description

Filter by Topic

Filter by Year

Lees Named Associate Dean

MIT News

KI associate director and Virginia & D.K. Ludwig Professor for Cancer Research Jacqueline Lees has been appointed associate dean in the MIT School of Science. Lees, along with John W. Jarve (1978) Professor in Brain and Cognitive Sciences Rebecca Saxe, will contribute to the school's diversity, equity, and inclusion activities, as well as develop and implement mentoring and other career-development programs to support the community. This work is well aligned with Lees' longstanding leadership at both the Koch Institute and MIT's Department of Biology, and her ongoing commitment to making discovery science research accessible to all.

MIRA MIRA on the Cell

MIT News

Congratulations to chemical engineer Katie Galloway on receipt of the Maximizing Investigators’ Research Award (MIRA) from the National Institutes of Health’s National Institute of General Medical Sciences. This prestigious award will support Galloway’s molecular systems biology work to develop multi-scale tools and approaches for understanding and engineering cell-fate transitions in development, reprogramming, and cancer. 

Fighting Health Disparities with Nanomedicine

MIT Koch Institute

Congratulations to Institute Professor and KI member Paula Hammond, the inaugural recipient of the Black in Cancer Distinguished Investigator Award. Established through a partnership between Black in Cancer and the Emerald Foundation in response to racial abuse experienced by Black birdwatcher Chris Cooper in Central Park last year, this award recognizes Black excellence in cancer research and medicine. With this support, Hammond will apply her signature layer-by-layer technology—variations on which were recently featured in National Geographic and The Wall Street Journalto engineer a nanoscale delivery system that direct a combination of chemotherapy and immunotherapy to ovarian cancer cells and the surrounding tumor microenvironment. Although the incidence rate of high grade serous ovarian cancer (HGSOC) is higher in white than black women, the mortality rate is higher for black women, making Hammond's approach a powerful tool for combating serious health disparities.

Three Strikes Against Pancreatic Cancer

MIT News

Jacks Lab investigations published in Cancer Cell have identified a promising three-drug combination to improve pancreatic tumors’ response to immunotherapy. The team now seeks to analyze which tumors will respond best to this approach and is working with the Lustgarten Foundation for Pancreatic Cancer Research and two pharmaceutical companies to test the combination therapy in clinical trials.

Inside Outreach

American Society for Cell Biology

KI outreach manager Erika Reinfeld sat down with KI postdoc and American Society for Cell Biology representative Tim Fessenden to discuss science outreach before and after Covid. Reflecting on the nature of online vs. in-person events, tours, and presentations, the conversation examined the pandemic’s impact on access, equity, and opportunity, as well as strategies for connecting STEM topics to people’s everyday experiences.
 

One Step at a Time

American Association for Cancer Research

Cancer metabolism pioneer Matthew Vander Heiden didn't set out to be a pioneer; he just wanted to understand how mitochondria worked. However, one question led to another and he soon found himself revisiting fundamental questions about cell metabolism and applying his discoveries to cancer biology. Now, as director of the Koch Institute, Vander Heiden continues to catalyze discoveries and interactions across the cancer research field.

Suono Bio Makes Waves

MIT News

KI startup Suono Bio is teaching an old technology new tricks. Beginning with treatment for ulcerative colitis, the team is using ultrasound waves to enhance drug delivery and promote localized absorption into the GI tract. Such an approach could one day make cancer therapy more precise and effective.

Staking Out Cancer

MIT News

Bhatia Lab engineers, in collaboration with biologists in the Gertler Lab, have created diagnostic nanoparticles that detect cancer cells and pinpoint their location anywhere in the body. A study published in Nature Materials tracked the progression and spread of metastatic colon cancer in mouse models before and after chemotherapy, suggesting that the platform could be used to diagnose and monitor cancer, as well as evaluate treatment response. The team is optimistic about the new platform's eventual use as a routine screening tool in annual health exams.

This project was supported in part by the Marble Center for Cancer Nanomedicine and a KI Quinquennial Cancer Research Fellowship, with earlier work supported by the Koch Institute Frontier Research Program.

Moles Meet Machine Learning

Technology Review

KI member Regina Barzilay continues her work to improve early cancer detection through machine learning algorithms. In an article published in Science Translational Medicine, Barzilay and colleagues describe the training and use of a deep convolutional neural network to compare markings on patients' skin to identify signs of pre-cancerous lesions.

mRNA Vaccines Beyond Covid

National Geographic

Covid-19 has brought substantial attention to the use of messenger RNA, or mRNA, as a tool for training the body to fight disease. KI member Daniel Anderson speaks with National Geographic about the application of this technology in cancer therapy—a longstanding research interest in his lab. His message? Therapeutic mRNA vaccines delivered via nanoparticles could offer great flexibility in helping the immune system identify and attack tumor cells across a wide range of cancer types.